2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $1.9B | $2.1B | $2.2B | $2.3B | $2.3B |
Cost of Revenue | $1.1B | $1.1B | $1.3B | $1.3B | $1.3B |
Gross Profit | $881M | $950M | $879M | $938M | $956M |
Gross Profit % | 45% | 46% | 40% | 42% | 42% |
R&D Expenses | $55M | $58M | $56M | $59M | $58M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $68M | $117M | $99M | $113M | $99M |
Dep. & Amort. | $89M | $87M | $90M | $91M | $88M |
Def. Tax | -$2.9M | $9.6M | -$14M | -$4.5M | -$9.6M |
Stock Comp. | $19M | $27M | $24M | $28M | $27M |
Chg. in WC | $43M | -$27M | -$81M | $6.8M | $48M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $365M | $479M | $189M | $216M | $209M |
ST Investments | $0 | $0 | $0 | $0 | $0 |
Cash & ST Inv. | $365M | $479M | $189M | $216M | $209M |
Receivables | $159M | $151M | $137M | $106M | $164M |
Inventory | $314M | $346M | $449M | $492M | $477M |
Q2 organic net sales decreased 1.5%, with 3% growth internationally offset by a 4% decline in North America; adjusted EPS was $0.87 (vs. $0.88 prior year), and adjusted EBITDA was $99.3M (vs. $99.7M prior year).
International business remains a key strength, now 40% of net sales, delivering consistent mid to high single-digit organic growth over four years; strong performance in China, Japan, and Europe, with notable gains in private brands and innovation.
North America underperformed expectations due to slower recovery in fem care and a weak start to the sun season (weather-related); however, recent market share and consumption trends are improving, and incremental investments are being made in sun care and women’s shave for H2.
Full-year fiscal 2025 outlook updated: organic net sales growth now expected to be flat to +1%, adjusted EPS guided to $2.85–$3.05 (including ~$0.35 currency headwind), and adjusted EBITDA expected at $329M–$341M; free cash flow guidance reduced to $130M–$140M due to lower earnings and higher inventory (partly from tariff mitigation).
Tariffs expected to have a $3M–$4M in-year impact on COGS in FY25 (mainly Q4), with annualized exposure estimated at 3–4% of COGS ($40M–$50M); mitigation efforts include alternative sourcing, productivity savings, and potential future pricing actions, but no significant price increases planned for FY25.